Montrouge, France, May 2, 2022

DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results

  • The U.S. Food and Drug Administration (FDA) has granted DBV Technologies a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol
  • The study protocol was recently submitted to the FDA as part of the Type C briefing materials

DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced business updates concerning the regulatory status for its lead product candidate, Viaskin Peanut. The Company also reported financial results for the first quarter of 2022. The quarterly financial statements were approved by the Board of Directors on April 29, 2022.

To download the full version of the Press Release in English language, please click on the following link: PDF Version

 

Attachment

  • PDF Version
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Juil 2022 à Août 2022 Plus de graphiques de la Bourse DBV Technologies
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Août 2021 à Août 2022 Plus de graphiques de la Bourse DBV Technologies